Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety, tolerability and pharmacokinetics (including comparisons of different formulations and investigation of food effect)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| single rising dose BIBP 5371 CL | Experimental |
| |
| BIBP 5371 CL tablet high dose | Experimental | to be compared with same daily dose level from single rising dose arm |
|
| BIBP 5371 CL tablet low dose | Experimental | to be compared with same daily dose level from single rising dose arm |
|
| Placebo drinking solution | Placebo Comparator |
| |
| BIBP 5371 CL drinking solution | Experimental |
| |
| BIBP 5371 CL tablet high dose with food | Experimental |
| |
| BIBP 5371 CL tablet low dose with food |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BIBP 5371 CL tablet | Drug | single rising daily doses |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with changes in vital signs | blood pressure, pulse rate, respiratory rate, body temperature | baseline, up to 8 days after drug administration |
| Number of patients with changes in electrocardiogram (ECG) | baseline, up to 8 days after drug administration | |
| Number of patients with changes in safety laboratory parameters | baseline, up to 8 days after drug administration | |
| Number of patients with adverse events | baseline, up to 8 days after drug administration | |
| Global tolerability assessment by the investigator on a verbal rating scale | up to 8 days after drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax (maximum concentration of the analyte in plasma) | up to 32 hours after drug administration | |
| tmax (time from dosing to maximum concentration) | up to 32 hours after drug administration | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
In addition, for female subjects:
Females, who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condoms) prior to administration of study medication, during the study and at least 1 month after release from the study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental |
|
| Placebo tablet | Placebo Comparator |
|
| BIBP 5371 CL solution |
| Drug |
|
| High fat, high caloric breakfast | Other |
|
| Placebo tablet | Drug |
|
| BIBP 5371 CL tablet high dose | Drug |
|
| Placebo drinking solution | Drug |
|
| BIBP 5371 CL tablet low dose | Drug |
|
| AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) |
| up to 32 hours after drug administration |
| %AUC0-tz (the percentage of the AUC0-∞ that is obtained by extrapolation) | up to 32 hours after drug administration |
| λz (terminal rate constant in plasma) | up to 32 hours after drug administration |
| t1/2 (terminal half-life of the analyte in plasma) | up to 32 hours after drug administration |
| MRTpo (mean residence time of the analyte in the body after po administration) | up to 32 hours after drug administration |
| CL/F (apparent clearance of the analyte in the plasma after extravascular administration) | up to 32 hours after drug administration |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 32 hours after drug administration |
| Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2) | up to 32 hours after drug administration |
| fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) | up to 32 hours after drug administration |
| CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) | up to 32 hours after drug administration |
| ID | Term |
|---|---|
| D013607 | Tablets |
| D012996 | Solutions |
| ID | Term |
|---|---|
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided